Joe Jimenez, a former Novartis CEO, and Mark Fishman, the former head of the Novartis Institutes for BioMedical Research, announced a new biotech startup on Monday: Tempero Bio.
The two are backing Tempero through their venture capital firm, Aditum Bio, which has raised $133 million to spend on four to six other new startups. Aditum’s first company, Teres Bio, launched in December, but Monday’s announcement marks the first time Jimenez and Fishman are speaking publicly about their work.
About the Author Reprints
